Freddie Dayao, APRN
Family · New Haven, CTNPI 1447967559
Payments from drug & device makers
Across 82 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$530
- AbbVie$411
- GSK$198
- Indivior Inc.$189
- Orexo US, Inc.$149
- Braeburn Inc.$132
- plus $475 from 13 others
What the payments were for
- Food & beverage$2,083100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $530 |
| AbbVie | 19 | $411 |
| GSK | 4 | $198 |
| Indivior Inc. | 8 | $189 |
| Orexo US, Inc. | 11 | $149 |
| Braeburn Inc. | 5 | $132 |
| Alkermes, Inc. | 4 | $90 |
| ANI Pharmaceuticals, Inc. | 3 | $82 |
| Boehringer Ingelheim | 2 | $54 |
| Novo Nordisk | 2 | $37 |
| Exact Sciences | 1 | $33 |
| Astellas Pharma US Inc | 1 | $32 |
| Lilly USA, LLC | 1 | $29 |
| Amgen | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Merck | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Valinor Pharma, LLC | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,083 in reported general payments places this provider in the 80th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $58 |
Paid to pharmacies, not to this prescriber.
Other family in New Haven
- Dayna GiordanoNew Haven$65K
- Alicia BurrNew Haven$17K
- Michael TawiahNew Haven$10K
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.